Literature DB >> 30098666

Surveying the Cost-Effectiveness of the 20 Procedures with the Largest Public Health Services Waiting Lists in Ireland: Implications for Ireland's Cost-Effectiveness Threshold.

Tse Chiang Chen1, Dane Wanniarachige1, Síofra Murphy1, Katie Lockhart1, James O'Mahony2.   

Abstract

OBJECTIVES: To survey the cost effectiveness of procedures with the largest waiting lists in the Irish public health system to inform a reconsideration of Ireland's current cost-effectiveness threshold of €45,000/quality-adjusted life-year (QALY).
METHODS: Waiting list data for inpatient and day case procedures in the Irish public health system were obtained from the National Treatment Purchase Fund. The 20 interventions with the largest number of individuals waiting for inpatient and day case care were identified. The academic literature was searched to obtain cost-effectiveness estimates from Ireland and other high-income countries. Cost-effectiveness estimates from foreign studies were adjusted for differences in currency, purchasing power parity, and inflation.
RESULTS: Of the top 20 waiting list procedures, 17 had incremental cost-effectiveness ratios (ICERs) lower than €45,000/QALY, 14 fell below €20,000/QALY, and 10 fell below €10,000/QALY. Only one procedure had an ICER higher than the current threshold. Two procedures had ICERs reported for different patient and indication groups that lay on either side of the threshold.
CONCLUSIONS: Some cost-effective interventions that have large waiting lists may indicate resource misallocation and the threshold may be too high. An evidence-informed revision of the threshold may require a reduction to ensure it is consistent with its theoretical basis in the opportunity cost of other interventions foregone. A limitation of this study was the difficulty in matching specific procedures from waiting lists with ICER estimates from the literature. Nevertheless, our study represents a useful demonstration of a novel concept of using waiting list data to inform cost-effectiveness thresholds.
Copyright © 2018 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ICER; Irish health care; cost-effectiveness analysis; cost-effectiveness threshold; waiting list

Mesh:

Year:  2018        PMID: 30098666     DOI: 10.1016/j.jval.2018.02.013

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  4 in total

1.  Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?

Authors:  James F O'Mahony
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

2.  Cost-effectiveness evidence on approved cancer drugs in Ireland: the limits of data availability and implications for public accountability.

Authors:  Suaad Almajed; Nora Alotaibi; Sana Zulfiqar; Zahraa Dhuhaibawi; Niall O'Rourke; Richard Gaule; Caoimhe Byrne; Aaron M Barry; Dylan Keeley; James F O'Mahony
Journal:  Eur J Health Econ       Date:  2021-08-30

Review 3.  Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.

Authors:  Chris Sampson; Bernarda Zamora; Sam Watson; John Cairns; Kalipso Chalkidou; Patricia Cubi-Molla; Nancy Devlin; Borja García-Lorenzo; Dyfrig A Hughes; Ashley A Leech; Adrian Towse
Journal:  Appl Health Econ Health Policy       Date:  2022-06-07       Impact factor: 3.686

Review 4.  The Need for Standardizing Diagnosis, Treatment and Clinical Care of Cholecystitis and Biliary Colic in Gallbladder Disease.

Authors:  Gerard Doherty; Matthew Manktelow; Brendan Skelly; Paddy Gillespie; Anthony J Bjourson; Steven Watterson
Journal:  Medicina (Kaunas)       Date:  2022-03-05       Impact factor: 2.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.